Lidocaine

KDS2010 (Tisolagiline), a reversible selective monoamine oxidase B (MAO-B) inhibitor, is being studied for treating Alzheimer's disease by influencing astrocytic GABA inhibition. It attenuates astrocytic GABA levels, enhances synaptic transmission, and improves learning and memory in mouse models. A Phase 2 clinical trial is currently recruiting in South Korea, with a U.S. cohort to be added in 2025. The Alzheimer’s drug market is projected to exceed $15 billion by 2030.

7709 studies identified, 62 included after deduplication and assessment. Most studies were blinded with sample sizes ranging from 15 to 270 patients. 70 different plants from 44 families were identified. Risk of bias assessment showed 27 studies with concerns, 22 with low risk, and 13 with high risk. 62 papers identified 17 orofacial pain conditions categorized into six groups. Meta-analyses found herbal extracts more effective in reducing periodontal, oral surgery, oral neuropathic, endodontic, oral mucosal, and TMD pain compared to standard therapies.

Scilex Holding Company announced data presentation on GLOPERBA® (colchicine oral solution) at the 2024 American College of Rheumatology Convergence, highlighting its precision dosing for gout patients, including reduced daily dose for severe renal impairment.

Scilex Holding announced a successful Phase II meeting with the FDA, leading to an agreed path forward for SP-103 5.4% (a next-generation, triple-strength formulation of ZTlido) to NDA upon completion of Phase III trials for chronic neck pain associated with muscle spasms. SP-103 has a projected peak sales potential of $1.2B annually in the 6th year post-launch.

Scilex Holding Company announces successful Phase II meeting with FDA, paving the way for NDA submission upon Phase III trials completion for SP-103, a next-generation lidocaine topical system for chronic neck pain. Market research projects SP-103's peak sales potential at $1.2 billion annually by the 6th year post-launch.

Scilex Holding Company announces successful Phase II meeting with FDA, paving the way for NDA submission for SP-103, a triple-strength lidocaine topical system for chronic neck pain. Market research projects SP-103 could achieve $1.2 billion in annual sales by the 6th year post-launch.

Scilex Holding Company explores spinoff or public listing of Scilex Pharmaceuticals in markets including Hong Kong to unlock potential value. Scilex Pharma has three FDA-approved products: ZTlido® for neuropathic pain, ELYXYB® for migraine, and Gloperba® for gout. A next-generation product, SP-103, targets acute pain with projected peak sales of $1.2 billion.

Scilex Holding Company explores spinoff or public listing of Scilex Pharmaceuticals in markets including Hong Kong to unlock potential value. Scilex Pharma has three FDA-approved products: ZTlido®, ELYXYB®, and Gloperba®, with SP-103, a next-generation lidocaine topical system, targeting $1.2 billion in peak sales.